Opinion
Logistical hassles hinder lifesaving lung cancer screenings
Scheduling lung cancer scans can be very difficult because of unwieldy internal processes.
Opinion
My patient chose quality of life over treatment
The patient’s voice has great value in the clinic and in research. Here are a few examples.
Opinion
If we care about cancer patients, we must care about climate change
Findings from the 2022 Lancet Countdown on health and climate change have been issued.
Opinion
Eliminating the language of blame in lung cancer
Talking to a patient with lung cancer can be like navigating a minefield of language pitfalls regardless of whether they are smokers.
Opinion
Had my patient come in today, we may have had other options
FDA’s approval of trastuzumab deruxtecan is a game-changer for NSCLC patients with HER alterations.
Opinion
In progressive lung cancer second biopsies may be the norm now
Many years after their discovery, we finally have a new string of EGFR-TKI approvals for NSCLC.
Opinion
Drugging the undruggable
Targeted therapies are the ideal in drug development. New drugs that target KRAS (G12C) mutations mark a significant leap forward in oncology.
Opinion
Adjuvant vs. neoadjuvant? What has ASCO 2022 taught us regarding resectable NSCLC?
Phase 3 trials are needed to determine whether neoadjuvant chemo/immunotherapy outperforms adjuvant chemo/immunotherapy.
Opinion
Climate change and air pollution seen through the cancer lens
The increase in the Earth’s temperature causes extreme weather events which will inevitably impact our patients.